139th Day Of Lockdown

Maharashtra51533235171017757 Tamil Nadu2969012386384927 Andhra Pradesh2278601387122036 Karnataka178087939083198 Delhi1454271305874111 Uttar Pradesh122609726502069 West Bengal95554671202059 Bihar7972051315429 Telangana7949555999627 Gujarat71064542382652 Assam5883842326145 Rajasthan5249738235789 Odisha4592731785321 Haryana4163534781483 Madhya Pradesh3902529020996 Kerala3433121832109 Jammu and Kashmir2489717003472 Punjab2390315319586 Jharkhand185168998177 Chhatisgarh12148880996 Uttarakhand96326134125 Goa871259575 Tripura6161417641 Puducherry5382320187 Manipur3752204411 Himachal Pradesh3371218114 Nagaland27819048 Arunachal Pradesh215514823 Chandigarh151590425 Meghalaya10624906 Sikkim8664971 Mizoram6082980
Nation Current Affairs 04 Jul 2020 Amid criticism, ICMR ...

Amid criticism, ICMR defends move to fast-track coronavirus vaccine trial

DECCAN CHRONICLE | DC CORRESPONDENT
Published Jul 4, 2020, 10:10 pm IST
Updated Jul 5, 2020, 8:04 am IST
The ICMR said that the letter by DG Dr Balram Bhargawa was intended to cut unnecessary red tape, without bypassing any necessary process.
Representational image.
 Representational image.

New Delhi: Facing criticism from health experts for asking scientists to speed up human trials of indigenous COVID-19 vaccine and complete it by August 15, the ICMR on Saturday said its process is in accordance with the globally accepted norms to fast-track vaccine development for diseases of pandemic potential wherein human and animal trials can continue in parallel.

In a statement, the ICMR said that the letter by DG Dr Balram Bhargawa was intended to cut unnecessary red tape, without bypassing any necessary process, and speed up recruitment of participants for human trials so that these phases can be completed at the earliest. It added that since pre-clinical studies have completed successfully now, the phases 1 and 2 human trials are to be initiated.

 

“In the larger public health interest, it is important for ICMR to expedite the clinical trials with a promising indigenous vaccine. Faced with the unprecedented nature of the COVID-19 pandemic and the consequent dislocation of normal life, all other vaccine candidates across the globe have been similarly fast-tracked. ICMR’s process is exactly in accordance with the globally accepted norms to fast-track the vaccine development for diseases of pandemic potential wherein human and animal trials can continue in parallel,” ICMR said.

 

The ICMR said its trials will be done following the best practices and rigour, and will be reviewed by a Data Safety Monitoring Board (DSMB).

“While issues raised in the public domain from time-to-time by commentators are welcome, as they form an important part of the feedback loop, the best of India’s medical professionals and research scientists should not be second guessed for their professionalism or adherence to the highest scientific rigour. ICMR is committed to treat the safety and interest of people of India as a topmost priority,” the statement said.

 

...




ADVERTISEMENT
ADVERTISEMENT
ADVERTISEMENT
ADVERTISEMENT
ADVERTISEMENT